TIDMSTX

RNS Number : 3313F

Shield Therapeutics PLC

21 March 2022

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

KYE Pharmaceuticals Inc. Files Accrufer(R) New Drug Submission in Canada for the Treatment of Iron Deficiency

London, UK - 21 March 2022: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on treating iron deficiency with its lead product Accrufer(R)/Feraccru(R) (ferric maltol), announces that KYE Pharmaceuticals Inc. ('KYE') has submitted a New Drug Submission ('NDS') to Health Canada for the regulatory review and approval of Accrufer(R).

If approved, Accrufer(R) would be the first prescription only oral iron therapy approved by Health Canada. Marketing approval for Accrufer(R) is expected to be during first half of 2023.

Doug Reynolds, President of KYE, said: "The Shield and KYE teams worked tremendously hard to compile the Canadian NDS in a matter of months and I am extremely pleased to have achieved this milestone."

José A. Menoyo, MD, Chief Medical Officer for Shield, added: "We are delighted with the rapid progress made in partnership with KYE since the signing of the license agreement in January 2022. Both organisations have demonstrated excellent collaboration and are driven to make Accrufer(R) available to patients in Canada with iron deficiency as quickly as possible. Shield Therapeutics is committed in bringing Accrufer(R)/Feraccru(R) to patients with iron deficiency around the world, and Canada is an important element of that mission."

Shield is eligible to receive GBP850,000 in development and sales milestones comprised of a payment of GBP250,000 upon regulatory approval of Accrufer(R) by Health Canada and up to GBP600,000 in milestone payments upon the achievement of specified calendar net sales targets. For the term of the agreement, Shield will also receive double-digit royalties on net sales of Accrufer(R).

For further information please contact:

 
 Shield Therapeutics plc                                        www.shieldtherapeutics.com 
 Greg Madison, CEO                                                    +44 (0) 191 511 8500 
 Hans-Peter Rudolf, CFO 
 
   Nominated Adviser and Joint 
   Broker 
 Peel Hunt LLP 
 James Steel/Christopher Golden                                        +44 (0)20 7418 8900 
 
   Joint Broker 
   finnCap Ltd 
   Geoff Nash/ George Dollemore/Alice 
   Lane/Nigel Birks                                                    +44 (0)20 7220 0500 
 
 Financial PR & IR Advisor 
 Walbrook PR 
 Lianne Applegarth/Alice Woodings             +44 (0)20 7933 8780 or shield@walbrookpr.com 
 
 Investor Contact (US Advisor) 
  LifeSci Advisors, LLC 
  John Mullaly                             +1 617 429 3548 or jmullaly@lifesciadvisors.com 
 

About Accrufer (R) /Feraccru (R)

Accrufer(R)/Feraccru(R) (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency, with or without anemia. Accrufer(R)/Feraccru(R) has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer(R)/ Feraccru(R) , including the product label, can be found at: www.accrufer.com and www.feraccru.com

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer(R)/Feraccru(R) (ferric maltol). The Group has launched Accrufer(R) in the US and Feraccru(R) is commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Accrufer(R) / Feraccru(R) in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.

Accrufer(R)/Feraccru(R) has patent coverage until the mid-2030s.

Accrufer(R)/Feraccru(R) are registered trademarks of the Shield Group.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCGPUQCWUPPGAR

(END) Dow Jones Newswires

March 21, 2022 03:00 ET (07:00 GMT)

Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024 Haga Click aquí para más Gráficas Shield Therapeutics.
Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024 Haga Click aquí para más Gráficas Shield Therapeutics.